Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study

Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study

Abstract Background Biliary tract cancer (BTC) has a high mortality. Primary diagnosis is frequently delayed due to mostly unspecific symptoms, resulting in a high number of advanced cases at the time of diagnosis. Advanced BTCs are in principle chemotherapy sensitive as determined by improved disea...

Full description

Bibliographic Details
Main Authors: L. Perkhofer, A. W. Berger, A. K. Beutel, E. Gallmeier, S. Angermeier, L. Fischer von Weikersthal, T. O. Goetze, R. Muche, T. Seufferlein, T. J. Ettrich
Format: Article
Language:English
Published: BMC 2019-10-01
Series:BMC Cancer
Subjects:
Biliary tract cancer
Cholangiocarcinoma
Chemotherapy
Nanoliposomal-irinotecan
Palliative treatment
Online Access:http://link.springer.com/article/10.1186/s12885-019-6142-y

Internet

http://link.springer.com/article/10.1186/s12885-019-6142-y

Similar Items